RxDoctor Payments Data

Joseph Mikhael, MD

Hematology · Scottsdale, AZNPI 1972781581

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $982,403 of the $1,504,411 with a category attached, or 65.3%. 28 manufacturers reported payments, led by Pfizer at 42.3% of the total.

$1,504,411in general payments, 2019–2025

Across 437 payments — averaging $3442.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$636K
  • Sanofi$155K
  • Amgen$143K
  • Sanofi-aventis U.S. LLC$129K
  • Karyopharm Therapeutics Inc.$120K
  • Bristol Myers Squibb$58K
  • plus $262K from 22 others
$1,118,238in research payments, 2019–2025

Across 130 payments — averaging $8601.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bristol Myers Squibb$383K
  • Sanofi US Services Inc.$267K
  • AbbVie$242K
  • Janssen Research & Development, LLC$88K
  • Pharmacyclics LLC, An Abbvie Company$54K
  • Regeneron$20K
  • plus $64K from 8 others

What the payments were for

  • Consulting fees$982,40365%
  • Speaking & faculty fees$460,02531%
  • Travel & lodging$47,7793%
  • Food & beverage$5,9310%
  • Education$8,2741%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few hematology providers in Arizonato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$7,975
Medicare patients
56
Services billed
104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →